HBM 7575
Alternative Names: HBM-7575Latest Information Update: 14 Oct 2025
At a glance
- Originator Harbour BioMed; Sichuan Kelun-Biotech Biopharmaceutical
- Class Anti-inflammatories; Bispecific antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 14 Oct 2025 Preclinical trials in Inflammation in China (Parenteral) (Harbour BioMed pipeline, October 2025)